PiperJaffray Initiates Coverage on Nevro Corp to Overweight

PiperJaffray Initiates Coverage on Nevro Corp(NYSE:NVRO). The shares have been rated Overweight. The rating by PiperJaffray was issued on Jul 22, 2016.

In a different note, William Blair said it Initiates Coverage on Nevro Corp, according to a research note issued on Jul 19, 2016. The shares have been rated ‘Outperform’ by the firm. Wells Fargo said it Initiates Coverage on Nevro Corp, according to a research note issued on Jul 12, 2016. The shares have been rated ‘Outperform’ by the firm.

Nevro Corp (NVRO) made into the market gainers list on Thursdays trading session with the shares advancing 0.38% or 0.31 points. Due to strong positive momentum, the stock ended at $81.65, which is also near the day’s high of $82.31. The stock began the session at $81.2 and the volume stood at 2,87,363 shares. The 52-week high of the shares is $81.9289 and the 52 week low is $36.51. The company has a current market capitalization of $2,313 M and it has 2,83,22,494 shares in outstanding.

Nevro Corp(NVRO) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $41.65M. Analysts had an estimated revenue of $33.48M. Earnings per share were $-0.33. Analysts had estimated an EPS of $-0.63.

Several Insider Transactions has been reported to the SEC. On Jul 12, 2016, Doug Alleavitch (VP, Quality) sold 2,000 shares at $80.00 per share price.Also, On Jul 12, 2016, Michael F Demane (director) sold 13,333 shares at $79.00 per share price.On Jul 7, 2016, Michael Enxing (VP of Sales) sold 1,500 shares at $75.52 per share price, according to the Form-4 filing with the securities and exchange commission.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *